Skip to main content
Clinical Trials/NCT01397110
NCT01397110
Recruiting
Not Applicable

Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life in Patients With Severe Associated Pulmonary Arterial Hypertension (APAH) as Part of a Congenital Heart Defect With / Without Eisenmenger's Syndrome

Heidelberg University1 site in 1 country50 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Arterial Hypertension
Sponsor
Heidelberg University
Enrollment
50
Locations
1
Primary Endpoint
Changes in the maximum 6-minute walk distance (6MGT)
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to investigate the influence of physical training on exercise capacity, quality of life, functional class, oxygen consumption and right ventricular function in patients with severe associated pulmonary arterial hypertension (APAH) as part of a congenital heart defect with / without Eisenmenger's Syndrome

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
December 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. med. Ekkehard Gruenig

Prof. Dr. med. Ekkehard Grünig

Heidelberg University

Eligibility Criteria

Inclusion Criteria

  • signed consent form
  • men and women\> 18 years \<80 years
  • APAH with congenital heart defects with / without Eisenmenger syndrome (WHO functional class II-IV), invasively diagnosed by right heart and left heart catheterization: mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, with targeted PAH medication for at least two months stable before study inclusion (exception: compensated WHO class II without vasodilating drug therapy)

Exclusion Criteria

  • Pregnancy or lactation
  • Change in medication during the last 2 months
  • severe walking disturbance
  • uncertain diagnoses
  • No previous invasively confirmation of PH
  • acute diseases, infections, fever
  • Serious lung disease with FEV1 \<50% or TLC \<70% of target
  • Further exclusion criteria are the following diseases: active myocarditis, unstable angina pectoris, exercise-induced ventricular arrhythmias, recurrent syncope within 4 weeks before study entry

Outcomes

Primary Outcomes

Changes in the maximum 6-minute walk distance (6MGT)

Time Frame: up to 15 weeks

Changes in quality of life

Time Frame: up to 15 weeks

Secondary Outcomes

  • Changes in hemodynamics(up to 15 weeks)

Study Sites (1)

Loading locations...

Similar Trials